Resubmission of NDA On Track for Early Q2 24 Cash Runway into 2025, including through Potential FDA Approval in Early Q4 24 Company to host conference call today at 8:30amET DUBLIN, Ireland and CHICAGO, March 28, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug... Read More